Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Glen Oaks, New York 11004


Purpose:

The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects. This study will explore how well Aripiprazole treats symptoms of early-onset psychotic disorders as well as symptoms that may indicate risk for such disorders, including unusual thoughts, suspiciousness, perceptual abnormalities, social isolation, and sudden changes in functioning.


Study summary:

During the 12-week study, eligible patients are seen 7-9 times by research raters and psychiatrists. These visits include side effect monitoring, scheduled medication increases, and ratings designed to measure subtle improvement of symptoms. Monthly blood and urine samples are collected for safety and substance abuse monitoring, and neuropsychological testing is conducted at the first and last appointments. Participants are compensated for their participation and receive medication and study-related visits at no cost during the trial. Depending on their level of response to the medication, participants may also be eligible for a 3-month extension phase.


Criteria:

Inclusion Criteria: - You are between the ages of 13 and 22. - You are English-speaking. - You have a diagnosed psychotic disorder, including: schizophrenia, schizophreniform disorder, schizoaffective disorder, or other psychotic disorder - OR - - You are experiencing one or more pre-psychotic symptoms like unusual thoughts, suspiciousness, or unusual perceptual experiences. - You meet additional RAP criteria assessed during screening and interview. Exclusion Criteria: - You have a diagnosis of bipolar disorder or major depression with psychotic features. - You have a history of neurological, neuroendocrine, or other medical conditions known to affect the brain. - You have past or current substance dependence. - You are currently taking Aripiprazole. - You have taken Aripiprazole in the past. - You are currently taking and responding well to another medication.


NCT ID:

NCT00169949


Primary Contact:

Principal Investigator
Barbara Cornblatt, PhD
LIJMC


Backup Contact:

N/A


Location Contact:

Glen Oaks, New York 11004
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.